Rivaroxaban in Venous Pulmonary Thromboembolism. The First Experience of New Oral Anticoagulant
*Sevket Ozkaya Department Of Pulmonary Medicine, Faculty Of Medicine, Bahcesehir University, Turkey
*Corresponding Author: Sevket Ozkaya
Department Of Pulmonary Medicine, Faculty Of Medicine, Bahcesehir University, Turkey Email:firstname.lastname@example.org
Published on: 2019-03-18
Background: With the advent of new oral anticoagulants for the treatment of deep-vein thrombosis and/or pulmonary embolism, a new era of oral anticoagulation for patients with venous thromboembolism has begun. Rivaroxaban is the first new oral anticoagulant to receive regulatory approval for the acute and continued treatment of deep-vein thrombosis and pulmonary embolism. Methods: We aimed to investigate the effects of rivaroxaban in patients with pulmonary embolism. Results: The ages of patients are varies between 34-84 years old and male/female ratio was 14/8. The average length of ICU(intensive care unit) and hospital stays are 69.5 hours and 6 days, respectively. The treatment complications were seen in only two patients including nausea and minor gastrointestinal hemorrage. Rivaroxaban treatment was stopped in patients with hemorrhage. There was no any major bleeding and reccurence or treatment failure . Conclusions: We think that the enoxaparin followed by rivaroxaban is effective, safe for long-term treatment in patients with pulmonary embolism. Also, rivaroxaban treatment doesn’t require laboratory coagulation monitoring.
Pulmonary embolism; new oral anticoagulants; rivaroxaban
Pulmonary embolism (PE) is a common disorder and an important cause of morbidity and mortality. PE occurs in approximately 650,000 patients annually in the US, of whom approximately 300,000 die. PE often arise from thrombus originating in the deep venous system of the lower extremities or pelvis. A blood clot dislodges and is swept into the pulmonary circulation and lodges in a pulmonary artery(1,2). The standard therapy for most patients with pulmonary embolism has been the administration of heparin, overlapped and followed by a vitamin K antagonist. This regimen is effective but complex(3-8). Recently developed oral anticoagulants that are directed against factor Xa or thrombin overcome some limitations of standard therapy, including the need for injection and for regular dose adjustments on the basis of laboratory monitoring(9). We aimed to investigate the effects of rivaroxaban in patients with pulmonary embolism.